A cross-sectional study of glucose and lipid metabolism in highly active antiretroviral therapy-naïve male patients with human immunodeficiency virus infection

doi:10.3877/cma.j.issn.1674-1358.2018.06.001

Abstract

Abstract:

Objective

To investigate the metabolism of glucose and lipid in highly active antiretroviral therapy (HAART)-na?ve male cases with human immunodeficiency virus (HIV) infection.

Methods

The metabolic parameters of body mass index (BMI), fasting blood glucose (FPG), blood lipid and uric acid were compared between 140 HAART-na?ve HIV/AIDS male patients (research group) and 140 healthy subjects (control group), respectively.

Results

Compared with control group, FPG of patients in research group increased significantly (5.76 mmol/L vs. 5.16 mmol/L; t = 5.265, P = 0.008), BMI reduced significantly (21.79 kg/m² vs. 23.07 kg/m²; t =-4.921, P < 0.001), triglyceride increased significantly (1.45 mmol/L vs. 1.16 mmol/L; t = 3.516, P = 0.001), serum uric acid increased significantly (411.66 μmol/L vs. 350.17 μmol/L; t = 7.167, P < 0.001), high density lipoprotein cholesterol decreased significantly (0.98 mmol/L vs. 1.29 mmol/L; t =-7.275, P < 0.001), all with significant differences. The levels of total cholesterol and low density lipoprotein cholesterol decreased with the decrease of CD4⁺ T cell count in the research group. The level of high density lipoprotein cholesterol was negatively correlated with HIV RNA load.

Conclusions

Before the treatment of HAART in male patients with HIV/AIDS, fasting blood glucose and blood lipids have been increased, which is related to the counts of CD4⁺ T cells and the load of HIV RNA. The metabolic indexes should be monitored regularly in the course of treatment to evaluate the risk of cardiovascular disease.

Key words: Human immunodeficiency virus (HIV), Newly diagnosed, Metabolism, Highly active antiretroviral therapy (HAART)

Yanxue Wang, Hongying Hu, Xingang Li, Wenjing Xu, Liang Ni. A cross-sectional study of glucose and lipid metabolism in highly active antiretroviral therapy-naïve male patients with human immunodeficiency virus infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(06): 521-525.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.06.001

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I06/521

Figures/Tables 4

References 20

[1]	中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南(2015版)[J]. 中华传染病杂志,2015,33(10):577-593.
[2]	Naidu S, Ponnampalvanar S, Kamaruzzaman SB, et al. Prevalence of metabolic dyndrome smong people living with HIV in developing countries: A systematic review[J]. AIDS Patient Care STDS,2017,31(1):1-13.
[3]	Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities[J]. Transl Res,2017,183(5):41-56.
[4]	Quiros-Roldan E, Raffetti E, Focà E, et al. Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012[J]. AIDS Care,2016,28(12):1551-1558.
[5]	Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease[J]. J Clin Endocrinol Metab,2007,92(7):2506-2512.
[6]	Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study[J]. AIDS, 2011,25(13):1637-1646.
[7]	Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis[J]. HIV Med,2012,13(8):453-468.
[8]	Rose H, Woolley I, Hoy J, et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment[J]. Metabolism,2006,55(1):90-95.
[9]	El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort[J]. HIV Med,2005,6(2):114-121.
[10]	Raposo MA, Gna A, Guimarães NS, et al. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy[J]. Rev Soc Bras Med Trop,2017,50(5):598-606.
[11]	肖江，郜桂菊，李鑫, 等. 高效抗逆转录病毒治疗对艾滋病患者机体代谢的影响[J/CD]. 中华实验和临床感染病杂志(电子版),2011,5(2):133-141.
[12]	兰丽娟，刘大凤，陈竹, 等. 初治获得性免疫缺陷综合征男性患者的糖脂代谢特点[J/CD]. 中华实验和临床感染病杂志(电子版),2016,10(3):280-284.
[13]	Timmons T, Shen C, Aldrovandi G, et al. Microbial translocation and metabolic and body composition measures in treated and untreated HIV infection[J]. AIDS Res Hum Retroviruses,2014,30(3):272-277.
[14]	Araujo S, Bañón S, Machuca I, et al. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs[J]. Eur J Endocrinol,2014,171(5):545-554.
[15]	Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment[J]. AIDS,2012,26(3):303-314.
[16]	Boufassa F, Goujard C, Viard JP, et al. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort[J]. Antivir Ther,2012,17(1):91-100.
[17]	Steiniche D, Jespersen S, Erikstrup C, et al. Diabetes mellitus and impaired fasting glucose in ART-naïve patients with HIV-1, HIV-2 and HIV-1/2 dual infection in Guinea-Bissau: a cross-sectional study[J]. Trans R Soc Trop Med Hyg,2016,110(4):219-227.
[18]	Shen Y, Wang Z, Liu L, et al. Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China[J]. BMC Infect Dis,2013,13:79.
[19]	Walker UA, Hoffmann C, Enters M, et al. High serum urate in HIV-infected persons: the choice of the antiretroviral drug matters[J]. AIDS,2006,20(11):1556-1558.
[20]	Guo F, Hsieh E, Lv W, et al. Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease[J]. BMC Infect Dis,2017,17(1):287.

组别	例数	年龄（岁）	BMI（kg/m²）	SBP（mmHg）	DBP（mmHg）	FPG（mmol/L）
病例组	140	31.25 ± 9.19	21.79 ± 2.66	116.34 ± 8.82	70.76 ± 6.70	5.76 ± 1.26
对照组	140	32.66 ± 8.05	23.07 ± 1.56	118.16 ± 7.57	72.11 ± 4.81	5.16 ± 0.49
t值	?	－1.370	－4.921	－1.854	－1.950	5.265
P值	?	0.172	< 0.001	0.065	0.052	< 0.001
组别	例数	UA（μmol/L）	TG（mmol/L）	TC（mmol/L）	HDL-C（mmol/L）	LDL-C（mmol/L）
病例组	140	411.66 ± 91.85	1.45 ± 0.93	3.91 ± 0.77	0.98 ± 0.49	2.370 ± 0.63
对照组	140	350.17 ± 43.24	1.16 ± 0.34	4.45 ± 0.57	1.29 ± 0.17	2.585 ± 0.50
t值	?	7.167	3.516	－6.574	－7.275	－3.142
P值	?	< 0.001	0.001	< 0.001	< 0.001	0.002

组别	例数	年龄（岁）	BMI（kg/m²）	SBP（mmHg）	DBP（mmHg）	FPG（mmol/L）
病例组	140	31.25 ± 9.19	21.79 ± 2.66	116.34 ± 8.82	70.76 ± 6.70	5.76 ± 1.26
对照组	140	32.66 ± 8.05	23.07 ± 1.56	118.16 ± 7.57	72.11 ± 4.81	5.16 ± 0.49
t值	?	－1.370	－4.921	－1.854	－1.950	5.265
P值	?	0.172	< 0.001	0.065	0.052	< 0.001
组别	例数	UA（μmol/L）	TG（mmol/L）	TC（mmol/L）	HDL-C（mmol/L）	LDL-C（mmol/L）
病例组	140	411.66 ± 91.85	1.45 ± 0.93	3.91 ± 0.77	0.98 ± 0.49	2.370 ± 0.63
对照组	140	350.17 ± 43.24	1.16 ± 0.34	4.45 ± 0.57	1.29 ± 0.17	2.585 ± 0.50
t值	?	7.167	3.516	－6.574	－7.275	－3.142
P值	?	< 0.001	0.001	< 0.001	< 0.001	0.002

组别	例数	BMI（kg/m²）	FPG（mmol/L）	UA（μmol/L）	TG（mmol/L）
CD4⁺ T > 500个/μl组	24	21.60 ± 1.97	5.99 ± 1.45	413.67 ± 101.91	1.52 ± 0.72
CD4⁺ T 200～500个/μl组	82	21.72 ± 2.86	5.84 ± 1.40	415.48 ± 78.16	1.49 ± 1.07
CD4⁺ T < 200个/μl组	31	22.03 ± 2.31	5.41 ± 0.48	403.13 ± 114.53	1.31 ± 0.63
F值	?	0.796	1.787	0.207	0.461
P值	?	0.229	0.172	0.813	0.632
组别	例数	TC（mmol/L）	HDL-C（mmol/L）	LDL-C（mmol/L）
CD4⁺ T > 500个/μl组	24	4.25 ± 0.72	0.94 ± 0.16	2.67 ± 0.63
CD4⁺ T 200～500个/μl组	82	3.97 ± 0.78	0.98 ± 0.24	2.37 ± 0.64
CD4⁺ T < 200个/μl组	31	3.51 ± 0.66	0.84 ± 0.22	2.13 ± 0.55
F值	?	7.239	4.689	5.151
P值	?	0.001	0.011	0.007

组别	例数	BMI（kg/m²）	FPG（mmol/L）	UA（μmol/L）	TG（mmol/L）
CD4⁺ T > 500个/μl组	24	21.60 ± 1.97	5.99 ± 1.45	413.67 ± 101.91	1.52 ± 0.72
CD4⁺ T 200～500个/μl组	82	21.72 ± 2.86	5.84 ± 1.40	415.48 ± 78.16	1.49 ± 1.07
CD4⁺ T < 200个/μl组	31	22.03 ± 2.31	5.41 ± 0.48	403.13 ± 114.53	1.31 ± 0.63
F值	?	0.796	1.787	0.207	0.461
P值	?	0.229	0.172	0.813	0.632
组别	例数	TC（mmol/L）	HDL-C（mmol/L）	LDL-C（mmol/L）
CD4⁺ T > 500个/μl组	24	4.25 ± 0.72	0.94 ± 0.16	2.67 ± 0.63
CD4⁺ T 200～500个/μl组	82	3.97 ± 0.78	0.98 ± 0.24	2.37 ± 0.64
CD4⁺ T < 200个/μl组	31	3.51 ± 0.66	0.84 ± 0.22	2.13 ± 0.55
F值	?	7.239	4.689	5.151
P值	?	0.001	0.011	0.007

组别	例数	BMI（kg/m²）	FPG（mmol/L）	UA（μmol/L）	TG（mmol/L）
HIV RNA>10⁵拷贝/ml组	34	21.52 ± 3.02	5.63 ± 1.27	401.18 ± 106.63	1.70 ± 0.95
HIV RNA 5 × 10⁴～10⁵拷贝/ml组	31	21.79 ± 3.11	5.85 ± 1.71	391.65 ± 89.34	1.27 ± 0.66
HIV RNA 10⁴～5 × 10⁴拷贝/ml组	42	22.02 ± 2.10	5.76 ± 0.72	435.64 ± 91.65	1.64 ± 1.18
HIV RNA < 10⁴拷贝/ml组	30	21.62 ± 2.56	5.89 ± 1.37	412.77 ± 75.45	1.28 ± 0.91
r值	?	－0.103	－0.089	－0.028	0.081
P值	?	0.236	0.306	0.749	0.348
组别	例数	TC（mmol/L）	HDL- C（mmol/L）	LDL- C（mmol/L）
HIV RNA>10⁵拷贝/ml组	34	3.64 ± 0.76	0.81 ± 0.19	2.16 ± 0.58
HIV RNA 5 × 10⁴～10⁵拷贝/ml组	31	4.01 ± 0.72	0.95 ± 0.28	2.49 ± 0.63
HIV RNA 10⁴～5 × 10⁴拷贝/ml组	42	3.99 ± 0.87	0.95 ± 0.20	2.35 ± 0.68
HIV RNA < 10⁴拷贝/ml组	30	3.87 ± 0.89	1.04 ± 0.20	2.51 ± 0.59
r值	?	－0.066	－0.246	－0.032
P值	?	0.450	0.004	0.710

Please choose a citation manager

Content to export